ARTA
BOLD

A.R.T. Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

A.R.T. Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-46,468
Closed -$1.3M – 1915
2019
Q3 		$1.3M Buy
46,468
+33,300
+253% +$1.14M 0.07% 429
2019
Q2 		$499K Sell
13,168
-1,000
-7% -$38.4K 0.03% 748
2019
Q1 		$553K Buy
+14,168
New +$406K 0.03% 711
2018
Q4 		– Sell
-7,068
Closed -$279K – 1842
2018
Q3 		$279K Sell
7,068
-3,857
-35% -$144K 0.01% 1071
2018
Q2 		$417K Sell
10,925
-6,200
-36% -$230K 0.02% 984
2018
Q1 		$514K Buy
+17,125
New +$580K 0.02% 954

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

A.R.T. Advisors's BOLD Position: Q4 2019 in Review

A.R.T. Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 46,468 shares — an estimated $1.3M sold.

A.R.T. Advisors first reported a position in BOLD in Q1 2018 and held it in 6 quarters. The position peaked at $1.3M in Q3 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • A.R.T. Advisors reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 46,468 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $1.3M.
  • A.R.T. Advisors first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 6 quarters.
  • A.R.T. Advisors's Audentes Therapeutics, Inc position peaked at $1.3M in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.